NASDAQ$BVS
Bioventus Inc - A · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported financial results for the first quarter of 2022 and reaffirmed full-year 2022 financial guidance
Bioventus reported a strong start to the year with a 43.4% increase in net sales compared to the previous year. The company's commercial organization performed well, and integration plans progressed. However, the company experienced a net loss of $14.8 million, compared to a net income of $24.5 million in the prior-year period, and a decrease in Adjusted EBITDA to $7.1 million from $11.1 million in the prior-year period.
- Net sales reached $117.3 million, a 43.4% increase year-over-year as reported and 8.6% organically.
- The company experienced a net loss of $14.8 million, compared to a net income of $24.5 million in the prior-year period.
- Adjusted EBITDA was $7.1 million, compared to $11.1 million in the prior-year period.
- The company reaffirmed its full-year 2022 financial guidance.
Headline financials
Revenue & EPS history
Bioventus · Revenue · Quarterly
$117M
Forward guidance
For the twelve months ending December 31, 2022, the Company expects net sales of $545 million to $565 million, representing year over year growth of approximately 26% to 31%, and Adjusted EBITDA of $94 million to $107 million, compared to $80.8 million for the year ended December 31, 2021.
Tailwinds
- Net sales of $545 million to $565 million, representing year over year growth of approximately 26% to 31%.
- Adjusted EBITDA of $94 million to $107 million, compared to $80.8 million for the year ended December 31, 2021.
Headwinds
- The Company does not provide U.S. GAAP financial measures, other than net sales, on a forward-looking basis because the Company is unable to predict with reasonable certainty the impact and timing of acquisition related expenses, accounting fair-value adjustments, and other reconciling items without unreasonable efforts.
- The Company is not providing guidance for adjusted diluted earnings per share due to the uncertainty of the timing for its potential CartiHeal acquisition, but will provide guidance after completion of any acquisition.
- The Company's guidance reflects its current expectations regarding the impact of COVID-19 on its business.
- The severity and duration of the COVID-19 pandemic are outside of the Company’s control and, given the uncertain nature of the pandemic, could cause the Company’s future operating results to be different from our current expectations, particularly if the impact of the pandemic worsens.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+2.1%
Avg return
Earnings day
+5.6%
Avg return
5 days after
+13.1%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+26.0%
Q1 2024
Best reaction
-39.9%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.2% | -4.6% | -15.4% | |
| Q4 2025 | +7.4% | +4.6% | +5.9% | |
| Q3 2025 | +15.1% | +13.6% | +16.2% | |
| Q1 2025 | -12.0% | -5.0% | -7.4% | |
| Q4 2024 | +23.3% | +9.7% | -13.6% | |
| Q3 2024 | -17.7% | -13.8% | -15.1% | |
| Q2 2024 | +19.2% | +21.2% | +54.3% | |
| Q1 2024 | +26.0% | +35.0% | +70.0% | |
| Q4 2023 | -0.4% | +2.6% | -9.4% | |
| Q3 2023 | +6.0% | -2.1% | +42.1% | |
| Q2 2023 | +20.3% | +32.9% | -2.6% | |
| Q1 2023 | +6.5% | +58.5% | +195.9% | |
| Q4 2022 | -6.6% | +2.5% | -16.5% | |
| Q3 2022 | -39.9% | -42.7% | -18.9% | |
| Q2 2022 | +4.8% | +3.9% | -6.4% | |
| Q1 2022 | -9.1% | +4.5% | +12.5% | |
| Q4 2021 | +0.8% | -3.0% | -4.0% | |
| Q3 2021 | -0.5% | -4.5% | -18.7% | |
| Q2 2021 | +1.7% | +0.3% | -0.7% | |
| Q1 2021 | +1.0% | +3.3% | +17.0% | |
| Q4 2020 | -4.8% | -0.4% | -9.1% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro